EyePoint, Inc.
US ˙ NasdaqGM ˙ US30233G2093

SecurityEYPT / EyePoint, Inc.
InstitutionWalleye Capital LLC
Latest Disclosed Ownership300,184 shares
Latest Disclosed Value $ 3,869,372
Walleye Capital LLC ownership in EYPT / EyePoint, Inc.

On May 13, 2026 - Walleye Capital LLC filed a 13F-HR/A form disclosing ownership of 300,184 shares of EyePoint, Inc. (US:EYPT) valued at $3,869,372 USD as of March 31, 2026. The entity filed a previous 13F-HR on November 14, 2025 disclosing 0 shares of EyePoint, Inc.. The current value of the position is $3,536,168 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F/A-1 EYEPOINT COM NEW 30233G209 300,184 300,184 3,869 0.0161
2026-05-08 2026-03-31 13F EYEPOINT COM NEW 30233G209 300,184 300,184 3,869 0.0161
2025-11-14 2025-09-30 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 0 -199,449 -100.00 0 -100.00
2025-08-13 2025-06-30 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 199,449 166,243 500.64 1,877 948.04 0.0073
2025-05-14 2025-03-31 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 33,206 33,206 180 0.0008
2024-11-14 2024-09-30 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 0 -373,974 -100.00 0 -100.00
2024-08-14 2024-06-30 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 373,974 187,016 100.03 3,254 -15.81 0.0058
2024-05-15 2024-03-31 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 186,958 186,958 3,864 0.0069
2023-08-14 2023-06-30 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 0 -52,289 -100.00 0 -100.00
2023-05-15 2023-03-31 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 52,289 -17,987 -25.59 154 -37.55 0.0023
2023-02-14 2022-12-31 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 70,276 70,276 246 0.0045
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.